A Phase 2 interventional study of Optilume™ BPH Prostatic DCB Dilation Catheter and Paclitaxel in Benign Prostatic Hyperplasia and Benign Prostatic Hypertrophy, sponsored by Urotronic Inc.. Completed at 5 sites in 2 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Urotronic Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years.
The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.
A prospective, non-randomized, multi-center study. The study will enroll up to 85 subjects to be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. Subjects will be followed up post-treatment at Foley removal, and up to 1 year. The subjects may choose to be followed-up annually for 5 years or until study close, whichever comes first.
Study device is Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System.
Study primarily outcomes are measured by 1). Change in IPSS score at 3-month post-procedure follow-up; 2). Major device or procedure related complications at 3-month post-procedure follow-up.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
This study's enrollment of 80 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →Urotronic Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Optilume™ BPH Prostatic DCB treatment procedure
Device: Optilume™ BPH Prostatic DCB Dilation Catheter · Drug: Paclitaxel
BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
Also known as: BPH Prostatic DCB
paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
Also known as: drug coated balloon
Therapeutic Responder at 3 Months
The proportion of subjects experiencing at least a 40% improvement in International Prostate Symptom Score (IPSS) scores from baseline to 3 months. The IPSS contains the well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH symptoms. The first seven questions in the IPSS address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency, and scored on a 6-point scale (0 to 5). The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.
Time frame: 90 days
Major Device/Procedure Related Complications
The proportion of subjects reporting a composite of device/procedure related severe urinary retention (lasting \>14 days), unresolved stress urinary incontinence, or bleeding requiring transfusion.
Time frame: 90 days
| Milestone | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Started | 80 |
| Completed | 52 |
| Not completed | 28 |
| Withdrew: Death | 5 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 16 |
The proportion of subjects experiencing at least a 40% improvement in International Prostate Symptom Score (IPSS) scores from baseline to 3 months. The IPSS contains the well-validated, highly reliable and responsive American Urological Association symptom score (AUASS) assessment to identify the severity of BPH symptoms. The first seven questions in the IPSS address frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency, and scored on a 6-point scale (0 to 5). The IPSS can be interpreted as follows: 0-7 mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic.
| Participants | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Therapeutic Responder at 3 Months | 65 |
The proportion of subjects reporting a composite of device/procedure related severe urinary retention (lasting \>14 days), unresolved stress urinary incontinence, or bleeding requiring transfusion.
| Participants | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Major Device/Procedure Related Complications | 2 |
Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Optilume™ BPH Prostatic DCB Dilation Catheter | 5/80 (6.3%) | 25/80 (31.3%) | 50/80 (62.5%) |
| Event | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| HematuriaRenal and urinary disorders | 8/80 |
| Urethral StenosisRenal and urinary disorders | 4/80 |
| Cerebrovascular AccidentNervous system disorders | 3/80 |
| Urinary IncontinenceRenal and urinary disorders | 2/80 |
| Complication of Device RemovalGeneral disorders | 2/80 |
| Urinary RetentionRenal and urinary disorders | 1/80 |
| Anesthetic Complication (Pulmonary)Injury, poisoning and procedural complications | 1/80 |
| Stress Urinary IncontinenceRenal and urinary disorders | 1/80 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 1/80 |
| Intestinal ObstructionGastrointestinal disorders | 1/80 |
| Event | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| HematuriaRenal and urinary disorders | 15/80 |
| Urinary Tract InfectionInfections and infestations | 14/80 |
| Urinary IncontinenceRenal and urinary disorders | 11/80 |
| DysuriaRenal and urinary disorders | 10/80 |
| Urinary RetentionRenal and urinary disorders | 9/80 |
| Ejaculation DisorderReproductive system and breast disorders | 8/80 |
| Age, Continuous(Years) | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Mean | 65.8 ± 7.8 |
| Sex: Female, Male(Participants) | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Female | 0 |
| Male | 80 |
| Race/Ethnicity, Customized(Participants) | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Race/Ethnicity — Black/African Origin | 10 |
| Race/Ethnicity — Caucasian | 2 |
| Race/Ethnicity — Hispanic/Latino | 68 |
| Prostate Volume (g)(grams) | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Mean | 35.9 ± 13.2 |
| Presence of Intravesical Prostatic Protrusion(Participants) | Optilume™ BPH Prostatic DCB Dilation Catheter |
|---|---|
| Count of participants | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Jun 2019, 17 months.
Results were first posted in Jul 2023, 4 years after primary completion.
Of 17 phase 2 interventional studies under Prostatic Hyperplasia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 76. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Urotronic Inc.